The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
(2015) The lancet. Diabetes & endocrinology — Vol. 3, n° 9, p. 687-696 (2015)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- Patients with type 2 diabetes and nephropathy have high cardiorenal morbidity and mortality despite optimum treatment including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Residual risk is related to residual albuminuria. We assessed whether CCX140-B, a selective inhibitor of C-C chemokine receptor type 2 (CCR2), could further reduce albuminuria when given in addition to standard care, including ACE inhibitors or ARBs.
- Affiliations
Citations
de Zeeuw, D., Bekker, P., Henkel, E., Hasslacher, C., Gouni-Berthold, I., Mehling, H., Potarca, A., Tesar, V., Heerspink, H. J. L., Schall, T. J., & CCX140-B Diabetic Nephropathy Study Group. (2015). The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. The lancet. Diabetes & endocrinology, 3(9), 687-696. https://doi.org/10.1016/S2213-8587(15)00261-2 (Original work published 2015)